Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vedolizumab vs conventional treatment for checkpoint inhibitor-induced colitis
2020-005793-10Phase 2Completed
- Sponsor
- Jakob Benedict Seidelin
- Start
- Feb 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of vedolizumab in immune-mediated colitis and Colitis (2 arms), sponsored by Jakob Benedict Seidelin. Primary endpoint: Cumulative corticosteroid dose at week 30. Started Feb 2021; status: completed.
02
Drugs
vedolizumab
03
Conditions
immune-mediated colitisColitis
Beyond the preview
Go deeper on 2020-005793-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005793-10.